Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 469Head & Neck 274Thoracic 113Tumor-Agnostic 32Breast 23Other solid neoplasm 22Gynecologic 18Genitourinary 15CNS 15Sarcoma 12Dermatologic 10Other neoplasm 4Lymphoid 3Plasma cell 2Myeloid 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 2Neoplasms 1

Interventions

Dexamethasone 870Lenalidomide 456Bortezomib 454Cyclophosphamide 365Melphalan 271Calcium Dobesilate 262daratumumab 233pomalidomide 207carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74Cyclosporine 68isatuximab 67auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 56Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Cetuximab × Plasma cell × Clear all
NCT01524978 2017-11-20

A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

Hoffmann-La Roche

Phase 2 Completed
208 enrolled 26 charts
Plasma cell

Multiple Myeloma, Neoplasms

NCT00368121 2012-07-13

EMMA-1

University of Cologne

Phase 2 Terminated
13 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡